In Vitro Evaluation

  • LIDE provides multiple in vitro assay platforms for serving clients’ projects. Either commercialized cancer cell lines, cells generated through conditional reprogramming (CRCs), or single cells derived from established PDXs can be used for primary screening, sensitivity validation, as well as MOAs evaluation. Immunotherapies, such as T cell-mediated killing, antibody-dependent cell-mediated cytotoxicity (ADCC), or antibody-dependent cell-mediated phagocytosis (ADCP) can also be determined when those cells interact with huPBMC or specific cell populations (T cells, Macrophage, etc.)
  • For detailed information, just stay tuned!